Orphalan

Orphalan

France - Paris
Biotechnology
WebsiteLinkedInCareers Page

Focus: Small molecule for Wilson's disease

Orphalan is a life sciences company focused on Small molecule for Wilson's disease.

Funding Stage
PUBLIC
Open Jobs
2

Products & Portfolio (1)

CUVRIOR
trientine tetrahydrochloride
Peak
ORAL · TABLET
Trientine, a copper chelator, eliminates absorbed copper from the body by forming a stable complex that is then eliminated through urinary excretion. Trientine also chelates copper in the intestinal tract, reducing copper absorption.
tolerant to penicillamine
2022
0

Pipeline & Clinical Trials

NCC-Sp Assay
Wilson Disease
N/A
Clinical Trials (1)
NCT05783687Real World Evidence Study in Subjects With Wilson's Disease
N/A
International Wilson's Disease Patient Registry (iWilson Registry)
Wilson's Disease
N/A
Clinical Trials (1)
NCT05239858International Wilson's Disease Patient Registry (iWilson Registry)
N/A
900mg TETA 4HCl Once Daily Formulation
Wilson's Disease
Phase 1
Clinical Trials (1)
NCT06128954Study Comparing Once Daily Dose of 900mg of TETA 4HCL Against Cuprior® (450mg Trientine Base, Twice Daily).
Phase 1
New TETA 4HCl Formulation
Wilson's Disease
Phase 2
Clinical Trials (1)
NCT07010575Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride
Phase 2
Penicillamine
Wilson Disease
Phase 3
Clinical Trials (2)
NCT07465718Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.
Phase 3
NCT03539952Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease
Phase 3

Open Jobs (2)

Quality Associate

Malta
Quality Assurance
1w ago

Communications Manager

Any, London, City of
Commercial
1w ago
Interview Prep Quick Facts
Founded: 2011
Portfolio: 1 approved product, 6 clinical trials
Publications: 7 in PubMed
Open Roles: 2 active jobs
Portfolio Health
Peak1 (100%)
1 total products

Hiring Trend

Stable
2
Open Roles
+2
Added
-0
Filled/Removed

Based on last 4 crawl cycles